Seattle-based AVM Biotechnology LLC announced it will provide ethical alternatives in the fields of biotechnology, pharmaceuticals, and vaccine development. Dr. Theresa Deisher, AVM Biotech research and development director, stated, “We will be working to bring commercially available, morally acceptable vaccines to the U.S. market and to use existing technology to produce new, morally certified vaccines. Revenues from the vaccine business will also further the research, development and commercialization of morally certified therapeutics in other areas of medicine as well.”
Children of God for Life, a pro-life organization that has worked to bring alternatives to aborted fetal vaccines to market, praised AVM Biotech. Its executive director, Debi Vinnedge, said, “There are no words sufficient to express our deepest gratitude to Dr. Deisher and AVM Biotech.”
LifeSiteNews.com reported, “While most vaccines and medicines are produced in an ethical manner, several are manufactured using cell lines derived from aborted fetal tissue with no competing ethical products available.”
Both the biotech firm and Children of God for Life said this action will lead Congress to move forward with fair labelling and informed consent legislation, a bill that would require full disclosure from the pharmaceutical industry whenever aborted fetal or embryonic cell lines are used in medical products.
“Every consumer, whether pro-life in philosophy or not, has the right to know if human fetal cell contaminants are present in the drugs they receive,” noted Deisher. “Consumers should be informed and empowered to make the best healthcare choices for themselves and their families.”
AVM Biotech intends to further assist in this effort by certifying that its therapeutic products are not discovered, screened, evaluated, produced or tainted in any way by the use of electively aborted human fetal material, human embryonic material or any other unethically obtained materials.
Vinnedge was named to a AVM Biotech board of advisers.
